Anticoagulating Budd-Chiari When the Underlying Blood Disorder Complicates the Choice
A patient with newly diagnosed Budd-Chiari syndrome needs long-term anticoagulation, but her hepatic vein thrombosis is driven by an underlying myeloproliferative neoplasm — a population DOAC trials weren't specifically built around.
Ingrid S., a 39-year-old woman, manages a small landscaping crew and spent most of this past spring assuming her worsening abdominal swelling and fatigue were just an unusually demanding season catching up with her, until a friend who works in healthcare urged her to get it checked. Imaging found hepatic vein thrombosis consistent with Budd-Chiari syndrome, and a subsequent hematology workup identified an underlying JAK2-positive myeloproliferative neoplasm as the likely driver — a real, if previously silent, hypercoagulable state rather than an isolated hepatic vein clot. She has no cirrhosis yet, preserved synthetic liver function, and no history of variceal bleeding.
Long-term anticoagulation is not in question; both a DOAC and warfarin are reasonable candidates in principle, and the choice between them isn't as settled as it might be in a more common indication. DOACs offer real convenience and monitoring-burden advantages over warfarin, but their trial base is concentrated in atrial fibrillation and standard venous thromboembolism, populations whose underlying hypercoagulable mechanism is genuinely different from an MPN-driven prothrombotic state. Warfarin has the longer specific track record in Budd-Chiari syndrome itself — the EN-Vie cohort, still the largest prospective series in the disease, was assembled almost entirely on vitamin K antagonists — though that track record predates the DOAC era rather than reflecting any head-to-head comparison.
Two specialties, two separate decisions that turn out to be connected
I'd lean toward a DOAC for convenience — no dietary restrictions, no routine INR monitoring, and there's no established evidence I'm aware of that Budd-Chiari with an underlying MPN specifically requires warfarin over a DOAC. All else being reasonably equal, the lower burden option seems like the right default.
I'd push toward warfarin instead, and it's not just about track record for its own sake. DOAC trials are concentrated in atrial fibrillation and standard venous thromboembolism, and her thrombosis isn't driven by either of those mechanisms — it's driven by an MPN-related hypercoagulable state, which is a genuinely different prothrombotic biology. Extrapolating DOAC efficacy from populations with a different clotting mechanism to hers carries real, unquantified uncertainty that warfarin's longer specific use in Budd-Chiari, even without head-to-head data, at least partially addresses.
'No established evidence requiring warfarin' is true only in the sense that the comparison hasn't been well studied either way — absence of evidence against a DOAC isn't the same as evidence a DOAC performs equivalently in her specific hypercoagulable mechanism.
I don't think this decision should be finalized in isolation from a decision that hasn't happened yet: how her MPN itself is going to be managed. Cytoreductive therapy for the underlying MPN changes her overall thrombotic risk independent of which anticoagulant she's on, and if that treatment plan isn't finalized, we're choosing an anticoagulant against a moving target. I'd want hematology's cytoreductive plan settled, or at least clearly outlined, before locking in the anticoagulant choice.
Warfarin started with a bridging plan and standard INR monitoring initiated. A DOAC was not selected, given the acknowledged population mismatch with her underlying thrombotic mechanism.
Unresolved and explicitly flagged: her cytoreductive therapy plan for the underlying MPN is still being finalized by hematology, and the team agreed the anticoagulant choice may need to be revisited once that plan, and its own effect on her overall thrombotic risk, is settled.